Other Development Work. For the avoidance of doubt, except for the Impact [***] IND submission work outlined in 4.1.1(i)(C), all clinical development of [***] and [***] shall be treated the same as provided for a Global Clinical Study with respect to roles and responsibilities of the parties and the bearing of costs and expenses. This includes Phase 1, Phase 2, Phase 3 and potentially Phase 4 studies for both Licensed Compounds, regardless of whether or not the studies are Pivotal Studies.
Appears in 4 contracts
Sources: Collaboration Agreement (Eikon Therapeutics, Inc.), Collaboration Agreement (Eikon Therapeutics, Inc.), Collaboration Agreement (Eikon Therapeutics, Inc.)